Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone

Karen T. Brown, Richard K. Do, Mithat Gonen, Anne M. Covey, George I. Getrajdman, Constantinos T. Sofocleous, William R. Jarnagin, Michael I. D'Angelica, Peter J. Allen, Joseph P. Erinjeri, Lynn A. Brody, Gerald P. O'Neill, Kristian N. Johnson, Alessandra R. Garcia, Christopher Beattie, Binsheng Zhao, Stephen B. Solomon, Lawrence H. Schwartz, Ronald DeMatteo, and Ghassan K. Abou-Alfa

Author affiliations appear at the end of this article.

Published online ahead of print at www.jco.org on February 1, 2016.

Supported by Grant No. 1 R21 CA128391-01 from the National Institutes of Health and by Grant No. P30 CA008748 (Cancer Center Support Grant) National Institutes of Health National Cancer Institute.

Terms in [blue](#) are defined in the glossary, found at the end of this article and online at www.jco.org.

Presented in part at the 10th Annual American Society of Clinical Oncology Gastrointestinal Cancers Symposium, San Francisco, CA, January 24-26, 2013, and at the 39th Annual Meeting of the Society of Interventional Radiology, San Diego, CA, March 22-27, 2014.

Authors' disclosures of potential conflicts of interest are found in the article online at www.jco.org. Author contributions are found at the end of this article.

Clinical trial information: NCT00539643.

Corresponding author: Karen T. Brown, MD, Department of Radiology, Memorial Sloan Kettering Cancer Center, 1275 York Ave, New York, NY 10065; e-mail: brownk6@mskcc.org.

© 2016 by American Society of Clinical Oncology

0732-183X/16/3417w-2046w/\$20.00

DOI: 10.1200/JCO.2015.64.0821

ABSTRACT

Purpose

Transarterial chemoembolization is accepted therapy for hepatocellular carcinoma (HCC). No randomized trial has demonstrated superiority of chemoembolization compared with embolization, and the role of chemotherapy remains unclear. This randomized trial compares the outcome of embolization using microspheres alone with chemoembolization using doxorubicin-eluting microspheres.

Materials and Methods

At a single tertiary referral center, patients with HCC were randomly assigned to embolization with microspheres alone (Bead Block [BB]) or loaded with doxorubicin 150 mg (LC Bead [LCB]). Random assignment was stratified by number of embolizations to complete treatment, and assignments were generated by permuted blocks in the institutional database. The primary end point was response according to RECIST 1.0 (Response Evaluation Criteria in Solid Tumors) using multiphase computed tomography 2 to 3 weeks post-treatment and then at quarterly intervals, with the reviewer blinded to treatment allocation. Secondary objectives included safety and tolerability, time to progression, progression-free survival, and overall survival. This trial is currently closed to accrual.

Results

Between December 2007 and April 2012, 101 patients were randomly assigned: 51 to BB and 50 to LCB. Demographics were comparable: median age, 67 years; 77% male; and 22% Barcelona Clinic Liver Cancer stage A and 78% stage B or C. Adverse events occurred with similar frequency in both groups: BB, 19 of 51 patients (38%); LCB, 20 of 50 patients (40%; $P = .48$), with no difference in RECIST response: BB, 5.9% versus LCB, 6.0% (difference, -0.1% ; 95% CI, -9% to 9%). Median PFS was 6.2 versus 2.8 months (hazard ratio, 1.36; 95% CI, 0.91 to 2.05; $P = .11$), and overall survival, 19.6 versus 20.8 months (hazard ratio, 1.11; 95% CI, 0.71 to 1.76; $P = .64$) for BB and LCB, respectively.

Conclusion

There was no apparent difference between the treatment arms. These results challenge the use of doxorubicin-eluting beads for chemoembolization of HCC.

J Clin Oncol 34:2046-2053. © 2016 by American Society of Clinical Oncology

INTRODUCTION

In 2002, two groups reported a survival benefit for patients with locally advanced [hepatocellular carcinoma](#) (HCC) treated with transarterial chemoembolization (TACE) compared with best supportive care (BSC).^{1,2} The study by Lo et al² compared cisplatin-based TACE to BSC whereas the study by Llovet et al¹ used doxorubicin-based TACE and included a bland hepatic artery

embolization (HAE) arm. The study by Llovet et al is thought by many to have demonstrated the superiority of TACE compared with both HAE and BSC; however, the sequential design allowed the trial to be stopped before any valid conclusion could be drawn regarding the effectiveness of bland HAE compared with BSC.¹ No prospective trial has demonstrated the superiority of conventional TACE compared with bland embolization, embolization with drug-eluting microspheres, or radioembolization.³ The randomized phase II

trial by Meyer et al⁴ used cisplatin-based TACE compared with HAE using polyvinyl alcohol particles alone and found no difference in survival. The purpose of this study was to determine what effect the addition of doxorubicin has on response and outcome after embolization with microspheres.

MATERIALS AND METHODS

Study Design

This study is a prospective single-center, single-blind, randomized phase II trial conducted at a tertiary cancer referral center in the United States and approved by the institutional review board at the center. No important changes were made to initial trial design or inclusion criteria.

Participants

Patients who were older than 18 years with a diagnosis of HCC, either biopsy proven or meeting European Association for the Study of the Liver (EASL) imaging criteria,⁵ and with Eastern Cooperative Oncology Group performance scores of 0 to 1 and Okuda stage I and II were eligible. Adequate organ function, including creatinine less than 2× the upper limit of normal and bilirubin less than 3.0 mg/dL, was required. Portal vein invasion at any level was allowed as long as liver function was preserved. Patients could have limited extrahepatic disease, such as a few small lung nodules or enlarged regional lymph nodes, at enrollment. Patients were staged by Okuda, Child-Pugh, TMN, and Barcelona Clinic Liver Cancer scores.⁶ Patients provided written informed consent both for trial participation and at the time of each procedure.

Random Assignment and Masking

Patients were randomly assigned to embolization using either Bead Block (BB; Biocompatibles UK, Farnham, Surrey, United Kingdom) or LC Bead (LCB; Biocompatibles UK), loaded with doxorubicin. Random assignment was stratified by the anticipated number of embolizations for complete treatment (one versus two) as left and right liver are never embolized concomitantly. Enrollment was by the interventional radiologist in the clinic, with random assignments generated by permuted blocks in the institutional database. Because LCB is red/purple when loaded, the operators were not blinded to treatment at the time of embolization; however, the patients and those interpreting the scans were blinded. The study was closed when target enrollment was achieved.

Hepatic Embolization Procedure

The morning of the procedure intravenous (IV) access was established and hydration begun with normal saline. An antiemetic (palonosetron hydrochloride 0.25 mg IV) and antibiotic (cefazolin 1 g IV) were administered. Procedures were performed using conscious sedation or general anesthesia. In the LCB group, doxorubicin 150 mg was loaded onto either 4 or 6 mL of LCB microspheres (37.5 or 50 mg/mL), depending on assessment of a combination of tumor volume and vascularity. The 150-mg dose was chosen as it was commonly used when the study protocol was developed.⁷⁻¹⁰ The embolization procedure for BB and for LCB is outlined in Figure 1.

Embolizations were performed as selectively as possible, treating individual segmental arteries when feasible. When more than one target branch was present, LCB was divided proportionately, depending on the size and number of vessels to be treated, and administered sequentially into the target vessels, which were then recatheterized and embolized with BB as necessary to achieve stasis identical to that achieved in the BB group. Stasis was defined as the absence of antegrade flow within a vessel such that contrast filling the target vessel persisted, without washout, five cardiac beats after the injection of contrast.¹¹

Complete treatment was defined as the treatment of all tumor that was identified on preprocedure imaging; in the case of multifocal bilobar disease, either the right or left liver was treated initially, embolizing the

remaining liver at a second session to complete treatment. Decisions regarding retreatment were made on the basis of multiphase computed tomography (CT) obtained at 3-month intervals.

End Points

The primary end point of the study was the estimate of response to treatment (RTT) of the target lesion(s) using RECIST 1.0¹² criteria as assessed on multiphase liver CT 2 to 3 weeks after complete treatment. Although RECIST 1.0¹² are the only validated imaging response criteria, they are insensitive to response at 2 to 3 weeks. After EASL suggestions,⁵ estimated tumor necrosis was computed. EASL recommends that the reduction in viable tumor volume be used to assess local RTT but does not specify how this should be accomplished.⁵ We defined categories according to the following criteria assessing enhancement of target tumor post-treatment: complete response, 0%, partial response, less than 50%, and stable disease, greater than 50%. Progressive disease was defined as a greater than 20% increase in enhancing tumor. With the advent of modified RECIST (mRECIST),^{13,14} an unplanned analysis using mRECIST was also performed. Recent evidence has demonstrated that objective response by either EASL or mRECIST, despite requiring validation, is valuable with regard to predicting survival, in contrast to RECIST.¹⁵ Progression by RECIST 1.0 and/or evidence of $\leq 5\%$ necrosis after treatment was considered treatment failure and patients were taken off study. Each multiphase CT was interpreted by an experienced hepatobiliary radiologist (L.H.S. or R.K.D.), who assessed the target lesions that were selected on the pretreatment CT by using RECIST 1.0, applying EASL as well, with retrospective mRECIST assessment performed by R.K.D. Patients were restaged after each imaging study, noting the development of local tumor progression, distant hepatic progression, or extrahepatic progression.

Secondary End Points

Secondary end points included safety, progression-free survival (PFS) and overall survival (OS) as well as an exploratory comparison of response rate. Hospital stay after treatment in each group was recorded. After the initial CT was obtained to assess response, imaging was performed every 3 months for the first year and then at 3- to 6-month intervals, depending on disease stability, as long as the patients remained on study. RTT was determined at 3, 6, 9, and 12 months by both RECIST 1.0 and mRECIST.

Serious adverse events (SAEs) were assessed and reported as defined by Common Terminology Criteria for Adverse Events 3.0.

Statistical Analysis

This was a randomized phase II trial with the primary objective of estimating response within each treatment arm. With 50 patients in each arm, this could be accomplished to within $\pm 14\%$. Secondary objectives were to estimate PFS and OS. In addition, an exploratory comparison of RTT, PFS, and OS was also planned.

The primary analysis was based on intent to treat. Patients who were not evaluable (dead or off study) for response were counted as nonresponders. Response rates were estimated with binomial proportions, reported with a 95% CI for the difference, and compared by using Fisher's exact test. PFS and OS probabilities were estimated using the Kaplan-Meier method and compared using the log-rank test. The number of patients with SAEs were compared by using Fisher's exact test. All statistical tests were two-tailed with type I error set at 5%.

RESULTS

Of 101 patients enrolled between December 2007 and April 2012, 92 underwent 129 embolizations to complete their initial treatment, with a total of 209 embolizations during the entire study. Patients underwent a median of two embolizations, and the average hospital stay was 3.5 days per patient in each group. A mean dose of doxorubicin 132.7 mg was administered to patients in the LCB group in

Fig 1. Flow diagram of embolization procedure for Bead Block and LC Bead. PVA, polyvinyl alcohol; SMA, superior mesenteric artery.

the first treatment cycle. The patient population and random assignment are shown in Figure 4. There were 19 patients with portal vein (PV) involvement; in 42% of these patients, the main PV was involved, in 21%, second-order branches (left or right), and in 36%, segmental branches. There were twice as many patients in the BB group who had PV involvement; however, two were not treated.

At the time of embolization, the risk of particle embolization to the pulmonary circulation by using LCB 100 to 300 µm resulted in one patient assigned to LCB embolization being treated instead with a larger size BB rather than LCB because the study design did not allow for the use of larger LCB. This patient, although treated with BB, was evaluated in the LCB group as this was the initial intent. Patient demographics, tumor characteristics, and stages are presented in Table 1. Patients in both arms had similar clinical and pathologic features.

Postembolization syndrome consisting of pain, fever, and/or nausea and vomiting was common, occurring after the first treatment cycle in 88% of patients who were embolized with BB and in 84% of patients treated with LCB. There was no significant difference in overall incidence or in any single element of post-embolization syndrome. Six of 51 patients (11.7%) in the BB group and six of 50 patients (12%) in the LCB group experienced major complications, according to Society of Interventional Radiology reporting standards,¹⁶ within 30 days (Table 2). There was one death in each group within 30 days; one patient with a large infiltrative tumor who was treated with LCB developed liver failure and died 25 days postembolization, and one patient who was treated with BB died unexpectedly at home 2 weeks after first embolization, before treatment was completed.

Fig 2. Response rate bar graph. There was no difference between Bead Block (BB) and LC Bead (LCB) at any time point. RECIST 2 to 3 weeks: $P = 1.0$ (95% CI, -9.3% to 9.1%); 3 months: $P = .79$ (95% CI, -11.3% to 18.5%); 6 months: $P = .89$ (95% CI, -14.8% to 17.9%); 9 months: $P = 1.0$ (95% CI, -11.3% to 18.5%); and 12 months: $P = 1.02$ (95% CI, -12.9% to 12.4%). Modified RECIST (mRECIST) 2 to 3 weeks: $P = .69$ (95% CI, -14.5% to 24.1%); 3 months: $P = .54$ (95% CI, -25.4% to 12.1%); 6 months: $P = .67$ (95% CI, -22.4% to 13.3%); 9 months: $P = .8$ (95% CI, -17.6% to 12.9%); and 12 months: $P = .77$ (95% CI, -9.8% to 17.1%). European Association for the Study of the Liver (EASL) at 2 to 3 weeks: $P = .26$ (95% CI, -21.7% to 6.5%).

Overall, 33 patients in each group did not experience an SAE. In the remaining 35 patients, a total of 61 SAEs were reported in the BB group and 71 in the LCB group, most commonly elevation in ALT, AST, or bilirubin immediately postembolization. No difference in the number or grade of SAE ($P = .93$, Table 2), number of SAEs per patient ($P = .75$), highest grade of SAE ($P = .57$), or relationship to treatment ($P = .24$) was found between the two groups.

The median follow-up time for survivors was 34 months; 73 patients had died at the time of data analysis. There were three RECIST responders in each group, yielding response rates of 5.9% and 6% in the BB and LCB groups, respectively (95% CI for the difference, -9% to 9%; $P = 1.0$). There was no difference in response rate between the two groups, either within 2 to 3 weeks (the primary end point) by EASL, RECIST 1.0, and mRECIST, or at quarterly follow-up by RECIST 1.0 or mRECIST (Fig 2).

Median PFS by RECIST was 6.2 months for BB and 2.8 months for LCB ($P = .11$; hazard ratio [HR], 1.36; 95% CI, 0.91 to 2.05; Fig 3A). Median OS was 19.6 months for BB and 20.8 months for LCB ($P = .64$; HR, 1.11; 95% CI, 0.71 to 1.76; Fig 3B). There was also no difference in OS for the 92 treated and imaged patients, with a median survival of 21.4 months in the BB group and 20.8 months for LCB ($P = .64$; HR, 1.31; 95% CI, 0.81 to 2.12). Comparing only patients who were treated, there was no difference between BB and LCB in any other measure, including PFS or response rate, at any time point.

DISCUSSION

The design of this study attempted to circumvent problems that are common to trials of embolization for HCC. We isolated the effect that could be ascribed to doxorubicin by assuring that the sole difference in

Table 1. Demographics and Clinical and Lesion Characteristics

Characteristic	Patients Receiving Bead Block (n = 51)	Patients Receiving LC Bead (n = 50)
Age, years ($\pm$ SD)	68.33 ($\pm$ 9.72)	65.52 ($\pm$ 11.82)
> 65, No. (%)	22 (43)	21 (42)
Male sex, No. (%)	37 (73)	41 (82)
Race, No. (%)		
White	41 (80)	38 (78)
Asian	7 (14)	6 (12)
Black	3 (6)	5 (10)
Etiology, No. (%)		
Hepatitis B	8 (17)	7 (14)
Hepatitis C	15 (29)	15 (30)
Alcohol	8 (17)	10 (20)
Multiple	6 (12)	5 (10)
Prior therapy, No. (%)*	13 (25)	16 (32)
Staging, No. (%)		
Okuda stage		
Stage I (0)	39 (76)	43 (86)
Stage II (1 or 2)	12 (24)	7 (14)
Child's Pugh score		
A (score 5-6)	41 (80)	45 (90)
B (score 7-11)	10 (20)	5 (10)
BCLC stage		
Early stage (A)	10 (20)	12 (24)
Intermediate stage (B)	22 (43)	23 (46)
Advanced stage (C)	19 (37)	15 (30)
Lesion characteristic, No. (%)		
Single	12 (24)	12 (24)
≤ 3	10 (20)	7 (14)
Multifocal	29 (57)	31 (62)
Mean diameter of lesion $\pm$ SD, cm	4.7 $\pm$ 3.7	4.3 $\pm$ 3.1
Median, cm (range)	3.4 (0.7-16.9)	3.5 (0.8-16.9)
Mean sum of diameters $\pm$ SD, cm	8.7 $\pm$ 4.5	10.8 $\pm$ 6.1
Median sum of diameters, cm (range)	7.7 (1.1-21.2)	8.7 (0.8-27.3)
ECOG PS, No. (%)		
0	44 (86)	43 (86)
1	7 (14)	7 (14)
Portal vein involvement, No. (%)	13 (25)	6 (12)
Extrahepatic disease, No. (%)	20 (39)	21 (42)

Abbreviations: BCLC, Barcelona Clinic Liver Cancer; ECOG, Eastern Cooperative Oncology Group; PS, performance status; SD, standard deviation.

*Prior therapy includes surgery or local therapy not directed toward current tumor burden or systemic therapy.

treatment between the two treatment arms was whether the microsphere was loaded with doxorubicin or not. In addition, we selected RTT as the primary end point to avoid favoring one of the treatment arms. Because ischemia results in virtually immediate tumor cell death after HAE, and findings consistent with tumor necrosis can be seen on imaging within 24 hours, we chose the scan that was obtained 2 to 3 weeks after treatment to assess the primary end point. LCB elutes doxorubicin over a period of hours to days, and tissue concentration of doxorubicin can remain elevated for weeks^{17,18}; thus, response may be enhanced beyond the immediate post-treatment time period. For that reason, we also evaluated RTT at 3-month intervals without finding any difference between BB and LCB.

Conventional TACE has garnered widespread popularity for treating unresectable HCC and is the only method of transarterial treatment that has been demonstrated to provide a survival advantage in randomized trials.^{1,2} Alternate methods include embolization with particles alone, with drug eluting beads, or with ⁹⁰Y loaded

Table 2. Complications and Serious Adverse Events

Adverse Event	Bead Block	LC Bead	Total
Cholecystitis	2	0	2
Liver abscess	1	0	1
Liver failure (transient)	1	0	1
Pancreatitis	0	1	1
Puncture site	1	0	1
DVT	0	1	1
VTE	0	0	0
PE	1	4	5
Total	6	6	12
Number of SAEs ($P = .93$)			
Grade 3	41	49	90
Grade 4	19	21	40
Grade 5	1	1	2
Total	61	71	132

Abbreviations: DVT, deep vein thrombosis; PE, pulmonary embolus; SAE, serious adverse event; VTE, venous thrombosis embolic.

microspheres—to date, the superiority of any one method has not been demonstrated.¹⁹ Although ischemia clearly plays a role in the treatment effect seen after embolization, the benefit of added chemotherapy in the embolization mixture has yet to be defined. Both a meta-analysis from 2002²⁰ and a systematic review from 2007²¹ concluded that there was no evidence that chemoembolization was more effective than embolization alone. Early reports of systemic doxorubicin failed to demonstrate efficacy for treatment of HCC.^{22,23} More recently, in a randomized phase II study comparing doxorubicin plus sorafenib with doxorubicin plus placebo,²⁴ the doxorubicin plus sorafenib group, in an exploratory comparison, showed a survival improvement of 13.7 months versus 6.5 months for the doxorubicin plus placebo arm ($P = .006$). Although this may suggest synergy between doxorubicin and sorafenib compared with the historical control phase III trial that helped establish sorafenib as a standard of care,¹⁸ it also supports the lack of activity of doxorubicin in the treatment of HCC. Despite this lack of efficacy, doxorubicin is the

most commonly used agent for TACE, alone or in combination with other chemotherapeutic agents.²¹ When drug-eluting microspheres were developed, they were loaded with doxorubicin to treat HCC.^{8,25}

Llovet et al¹ used doxorubicin in their TACE arm, whereas the bland HAE arm used gelfoam for embolization. Gelfoam is a temporary occlusive agent that results in more proximal vessel occlusion. Tumor cell death after HAE results from ischemia; consequently, smaller particles that will block the intratumoral vessels should be more effective and permanent agents are preferred.²⁶ Despite the use of gelfoam alone in the HAE arm, the probability of survival at 1 and 2 years was 75% and 50%, respectively, for HAE, and 82% and 63%, respectively, for TACE, with a mean survival of 25.3 months for HAE and 28.7 months for TACE. This similarity suggests that the therapeutic effect of TACE may primarily be an embolic or ischemic effect and not related to doxorubicin.

Using cisplatin, Lo et al² also demonstrated a survival benefit for TACE compared with BSC. Sahara et al²⁷ found that TACE with cisplatin, mitomycin C, and epirubicin was more toxic than TACE with epirubicin alone, and resulted in more postembolization hepatic artery injury, but no improvement in radiographic response, PFS, or survival at 1 or 2 years. The one agent common to all of these studies was an embolic. Of interest, the results of TACE seem to be independent of the type or number of chemotherapeutic drugs used, a point emphasized in the systematic review by Marelli et al²¹ that included 40 TACE studies. If indeed the chemotherapeutic was the active agent, this would be quite unusual, unless it is to be hypothesized that all of the drugs are active against HCC. A similar finding in a systemic chemotherapy trial or meta-analysis would be viewed with skepticism.

Results of this trial are reported on the basis of intent-to-treat by using RECIST 1.0 to report overall RECIST 1.0 progression, not local tumor progression; thus, results will not be comparable to many other reports of embolization for HCC. Nine patients who were either not treated or not imaged, and thus not evaluable, were counted as progressed, which contributes to the low median PFS of 6.2 and 2.8 months in the BB and LCB groups, respectively. Sixty-one

Fig 3. (A) Progression-free survival for Bead Block versus LC Bead ($P = .11$; hazard ratio, 1.36; 95% CI, 0.91 to 2.05). (B) Overall survival for Bead Block versus LC Bead ($P = .64$; hazard ratio, 1.31; 95% CI, 0.81 to 2.12).

Fig 4. CONSORT diagram.

patients progressed within the first year, but only nine progressed locally and could rightly be considered to have experienced treatment failure. Tumors of two patients classified by RECIST 1.0 as progressive disease at 2 to 3 weeks on the basis of only larger tumor measurement were completely nonenhancing, or necrotic, by imaging, a well-recognized problem when using RECIST after local regional treatments, which prompted the development of mRECIST in 2010.¹³ Whereas the 2% mortality rate is higher than reported in some studies, it is within accepted Society of Interventional Radiology parameters and below the threshold level of 4%. Although a 1% mortality rate was reported for patients without extrahepatic disease or PV involvement in studies by Llovet et al¹ and Lammer et al,⁸ rates of 6% to 7% have been reported for more advanced disease.²⁸

Our trial has some of the shortcomings reported in other HCC trials: a small study population, with patients receiving other surgical and systemic therapies before and after enrollment. The results serve as a cautionary reminder of the potential pitfalls that may be encountered with the informal application of therapies available for HCC outside of the domain in which they were defined. The median OS is shorter than reported in previous studies^{1,2}; however, comparisons across trials are fraught with selection bias. This trial included a number of patients with larger tumors, and allowed PV tumor thrombus and oligometastatic disease. It is important to note that this is a single-institution study defined by a certain technical expertise, particular methodology, and clinical practice; however, these factors were identical

in both arms and, yet, there was no difference in any outcome measure. Our results should be interpreted within the context of a randomized phase II study. It is doubtful that any further efforts will be spent on a randomized phase III trial of this nature because a large trial would be required to detect any small difference that might exist—a difference unlikely to be clinically meaningful. Despite the initial disappointment in evaluating this approach with the addition of sorafenib to TACE,²⁹ future efforts might be better focused on synergistic or adjuvant effects of other therapies added to local treatments. Another approach might be the addition of transarterial or other local therapies to systemic treatment in the metastatic setting.³⁰ Whereas our study was not powered to detect small to moderate differences in outcome, none of the end points approached statistical or clinical significance, calling into question the role of doxorubicin for transarterial therapies.

In conclusion, we report no difference in response, PFS, or OS after treatment with BB versus LCB. Given the comparable safety profile, progression rate, and survival, HAE should continue to be considered a reasonable therapeutic option and an alternative to embolization with doxorubicin-loaded microspheres.

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Disclosures provided by the authors are available with this article at www.jco.org.

AUTHOR CONTRIBUTIONS

Conception and design: Karen T. Brown, Mithat Gonen, Anne M. Covey, Lynn A. Brody, Gerald P. O'Neill, Lawrence H. Schwartz, Ronald DeMatteo, Ghassan K. Abou-Alfa

Provision of study materials or patients: William R. Jarnagin, Michael I. D'Angelica, Peter J. Allen, Ronald DeMatteo

Collection and assembly of data: Karen T. Brown, Richard K. Do, Anne M. Covey, George I. Getrajdman, Constantinos

T. Sofocleous, Kristian N. Johnson, Alessandra R. Garcia, Christopher Beattie, Binsheng Zhao, Lawrence H. Schwartz

Data analysis and interpretation: Karen T. Brown, Richard K. Do, Mithat Gonen, Anne M. Covey, Joseph P. Erinjeri, Kristian N. Johnson, Christopher Beattie, Stephen B. Solomon, Lawrence H. Schwartz, Ronald DeMatteo, Ghassan K. Abou-Alfa

Manuscript writing: All authors

Final approval of manuscript: All authors

REFERENCES

- Llovet JM, Real MI, Montaña X, et al; Barcelona Liver Cancer Group: Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. *Lancet* 359:1734-1739, 2002
- Lo CM, Ngan H, Tso WK, et al: Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. *Hepatology* 35:1164-1171, 2002
- Brown DB, Geschwind JF, Soulen MC, et al: Society of Interventional Radiology position statement on chemoembolization of hepatic malignancies. *J Vasc Interv Radiol* 17:217-223, 2006
- Meyer T, Kirkwood A, Roughton M, et al: A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. *Br J Cancer* 108:1252-1259, 2013
- Bruix J, Sherman M, Llovet JM, et al; EASL Panel of Experts on HCC; European Association for the Study of the Liver: Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. *J Hepatol* 35:421-430, 2001
- Llovet JM, Fuster J, Bruix J; Barcelona-Clinic Liver Cancer Group: The Barcelona approach: Diagnosis, staging, and treatment of hepatocellular carcinoma. *Liver Transpl* 10:S115-S120, 2004 (suppl 1)
- Malagari K, Chatzimichael K, Alexopoulou E, et al: Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: Results of an open-label study of 62 patients. *Cardiovasc Intervent Radiol* 31:269-280, 2008
- Lammer J, Malagari K, Vogel T, et al; PRECISION V Investigators: Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: Results of the PRECISION V study. *Cardiovasc Intervent Radiol* 33:41-52, 2010
- Poon RT, Tso WK, Pang RW, et al: A phase I/II trial of chemoembolization for hepatocellular carcinoma using a novel intra-arterial drug-eluting bead. *Clin Gastroenterol Hepatol* 5:1100-1108, 2007
- Aliberti C, Benea G, Tili M, et al: Chemoembolization (TACE) of unresectable intrahepatic cholangiocarcinoma with slow-release doxorubicin-eluting beads: Preliminary results. *Cardiovasc Intervent Radiol* 31:883-888, 2008
- Chrisman HB, Minocha J, Ryu RK, et al: Uterine artery embolization: A treatment option for symptomatic fibroids in postmenopausal women. *J Vasc Interv Radiol* 18:451-454, 2007
- Therasse P, Arbuck SG, Eisenhauer EA, et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. *J Natl Cancer Inst* 92:205-216, 2000
- Lencioni R, Llovet JM: Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. *Semin Liver Dis* 30:52-60, 2010
- Llovet JM, Di Bisceglie AM, Bruix J, et al; Panel of Experts in HCC-Design Clinical Trials: Design and endpoints of clinical trials in hepatocellular carcinoma. *J Natl Cancer Inst* 100:698-711, 2008
- Vincenzi B, Di Maio M, Silletta M, et al: Prognostic relevance of objective response according to EASL criteria and mRECIST criteria in hepatocellular carcinoma patients treated with loco-regional therapies: A literature-based meta-analysis. *PLoS One* 10:e0133488, 2015
- Brown DB, Gould JE, Gervais DA, et al; Society of Interventional Radiology Technology Assessment Committee and the International Working Group on Image-Guided Tumor Ablation: Transcatheter therapy for hepatic malignancy: Standardization of terminology and reporting criteria. *J Vasc Interv Radiol* 20(7, Suppl):S425-S434, 2009
- Namur J, Wassef M, Millot JM, et al: Drug-eluting beads for liver embolization: Concentration of doxorubicin in tissue and in beads in a pig model. *J Vasc Interv Radiol* 21:259-267, 2010
- Namur J, Citron SJ, Sellers MT, et al: Embolization of hepatocellular carcinoma with drug-eluting beads: Doxorubicin tissue concentration and distribution in patient liver explants. *J Hepatol* 55:1332-1338, 2011
- Brown DB, Nikolic B, Covey AM, et al; Society of Interventional Radiology Standards of Practice Committee: Quality improvement guidelines for transhepatic arterial chemoembolization, embolization, and chemotherapeutic infusion for hepatic malignancy. *J Vasc Interv Radiol* 23:287-294, 2012
- Cammà C, Schepis F, Orlando A, et al: Transarterial chemoembolization for unresectable hepatocellular carcinoma: Meta-analysis of randomized controlled trials. *Radiology* 224:47-54, 2002
- Marelli L, Stigliano R, Triantos C, et al: Transarterial therapy for hepatocellular carcinoma: Which technique is more effective? A systematic review of cohort and randomized studies. *Cardiovasc Intervent Radiol* 30:6-25, 2007
- Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, et al: Doxorubicin (75 mg/m²) for hepatocellular carcinoma: Clinical and pharmacokinetic results. *Cancer Treat Rep* 68:487-491, 1984
- Lai CL, Wu PC, Chan GC, et al: Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. *Cancer* 62:479-483, 1988
- Abou-Alfa GK, Johnson P, Knox JJ, et al: Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: A randomized trial. *JAMA* 304:2154-2160, 2010
- Malagari K, Pomoni M, Kelekis A, et al: Prospective randomized comparison of chemoembolization with doxorubicin-eluting beads and bland embolization with BeadBlock for hepatocellular carcinoma. *Cardiovasc Intervent Radiol* 33:541-551, 2009
- Lee KH, Liapi E, Vossen JA, et al: Distribution of iron oxide-containing Embosphere particles after transcatheter arterial embolization in an animal model of liver cancer: Evaluation with MR imaging and implication for therapy. *J Vasc Interv Radiol* 19:1490-1496, 2008
- Sahara S, Kawai N, Sato M, et al: Prospective evaluation of transcatheter arterial chemoembolization (TACE) with multiple anti-cancer drugs (epirubicin, cisplatin, mitomycin c, 5-fluorouracil) compared with TACE with epirubicin for treatment of hepatocellular carcinoma. *Cardiovasc Intervent Radiol* 35:1363-1371, 2012
- Dhanasekaran R, Kooby DA, Staley CA, et al: Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocellular carcinoma (HCC). *J Surg Oncol* 101:476-480, 2010
- Lencioni R, Zou J, Leberre M, et al: Sorafenib (SOR) or placebo (PL) in combination with transarterial chemoembolization (TACE) for intermediate-stage hepatocellular carcinoma (SPACE). *J Clin Oncol* 28:15s, 2010 (abstr TPS178)
- Kim S, Brown KT, Fong YM, et al: Embolization versus embolization and systemic therapy in patients with hepatocellular carcinoma and metastatic disease: A retrospective analysis. *J Clin Oncol* 32, 2014 (suppl 3; abstr 363)

Affiliations

Karen T. Brown, Richard K. Do, Mithat Gonen, Anne M. Covey, George I. Getrajdman, Constantinos T. Sofocleous, William R. Jarnagin, Michael I. D'Angelica, Peter J. Allen, Joseph P. Erinjeri, Lynn A. Brody, Gerald P. O'Neill, Kristian N. Johnson, Alessandra R. Garcia, Christopher Beattie, Stephen B. Solomon, Ronald DeMatteo, and Ghassan K. Abou-Alfa, Memorial Sloan Kettering Cancer Center; Binsheng Zhao and Lawrence H. Schwartz, Columbia University College of Physicians and Surgeons; and Karen T. Brown, Richard K. Do, Anne M. Covey, George I. Getrajdman, Constantinos T. Sofocleous, William R. Jarnagin, Michael I. D'Angelica, Peter J. Allen, Joseph P. Erinjeri, Lynn A. Brody, Stephen B. Solomon, Ronald DeMatteo, and Ghassan K. Abou-Alfa, Weill Cornell Medical College, New York, NY.

GLOSSARY TERMS

Hepatocellular carcinoma (HCC): A type of adenocarcinoma, the most common form of liver cancer.

Let Cancer.Net Help You Address Clinical Trials With Your Patients

Multiple barriers exist when it comes to patient participation in clinical trials. In response to these barriers, Cancer.Net now offers PRE-ACT (Preparatory Education About Clinical Trials). This FREE interactive video-based program provides patients with tailored clinical trial information in an effort to help them be better prepared to make an informed decision about clinical trial participation. Learn more at cancer.net/PREACT.

American Society of Clinical Oncology

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Randomized Trial of Hepatic Artery Embolization for Hepatocellular Carcinoma Using Doxorubicin-Eluting Microspheres Compared With Embolization With Microspheres Alone

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or jco.ascopubs.org/site/ifc.

Karen T. Brown

Consulting or Advisory Role: Surgical Specialties, Guerbet

Research Funding: GE Healthcare

Richard K. Do

No relationship to disclose

Mithat Gonen

No relationship to disclose

Anne M. Covey

No relationship to disclose

George I. Getrajdman

Consulting or Advisory Role: CareFusion

Constantinos T. Sofocleous

Stock or Other Ownership: Sirtex Medical

Honoraria: Surefire Medical, Perseon, NeuWave Medical, Siemens Healthcare Diagnostics

Consulting or Advisory Role: Perseon, Guerbet

Research Funding: HS Medical, NeuWave Medical, Perseon, MedWaves

William R. Jarnagin

No relationship to disclose

Michael I. D'Angelica

No relationship to disclose

Peter J. Allen

No relationship to disclose

Joseph P. Erinjeri

No relationship to disclose

Lynn A. Brody

Stock or Other Ownership: Sirtex Medical, General Electric (I)

Gerald P. O'Neill

No relationship to disclose

Kristian N. Johnson

No relationship to disclose

Alessandra R. Garcia

No relationship to disclose

Christopher Beattie

No relationship to disclose

Binsheng Zhao

No relationship to disclose

Stephen B. Solomon

Leadership: Devicor Medical Products

Stock or Other Ownership: Johnson & Johnson, Progenics, Aspire Bariatrics

Consulting or Advisory Role: GE Healthcare, AngioDynamics, Covidien

Research Funding: GE Healthcare (Inst)

Patents, Royalties, Other Intellectual Property: GE Healthcare patents pending (Inst), Aspire Bariatrics

Lawrence H. Schwartz

Consulting or Advisory Role: Novartis, Celgene, ICON Clinical Research, BioClinica

Ronald DeMatteo

No relationship to disclose

Ghassan K. Abou-Alfa

Consulting or Advisory Role: Astellas Pharma, Celsion, Eli Lilly/ImClone, Exelixis, IntegraGen, Jennerex, MedImmune, Novartis, Vicus Therapeutics, Aduro Biotech (I), AstraZeneca (I), Celgene, Pharmacyclics (I), Sanofi (I), Silenseed (I), Cipla, Array BioPharma (I), BioAlliance Pharma, Boston Scientific, Boston Therapeutics, CASI Pharmaceuticals, Merrimack, Onxeo, Sillajen, Bristol-Myers Squibb (I), EMD Sorono (I), Gilead Sciences (I), Mederger (I), Momenta Pharmaceuticals (I)

Research Funding: Abbott Laboratories (Inst), Amgen (Inst), Bayer AG (Inst), Eli Lilly/ImClone (Inst), Exelixis (Inst), Genentech (Inst), Novartis (Inst), Polaris (Inst), Roche (Inst), Vicus Therapeutics (Inst), CASI Pharmaceuticals (Inst)

Travel, Accommodations, Expenses: Polaris

Acknowledgment

LC Bead provided by Biocompatibles UK, Farnham, Surrey, United Kingdom.